LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration (wAMD)
  • Macular edema following retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)
  • Diabetic Retinopathy (Non Proliferative Diabetic Retinopathy (NPDR)), Proliferative Diabetic Retinopathy (PDR) in patients with Diabetic Macular Edema (DME)

The following randomized, double-masked pivotal trials were conducted for the 4 LUCENTIS indications: wAMD: MARINA—Phase III, multicenter, 2-year, sham injection–controlled study; primary end point at 1 year. ANCHOR—Phase III, multicenter, 2-year, active treatment–controlled study; primary end point at 1 year. PIER—Phase IIIb, 2-year, sham injection–controlled study; primary end point at 1 year. HARBOR—Phase III, multicenter, 2-year, active treatment–controlled dose-response study; primary end point at 1 year. RVO: BRAVO—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. CRUISE—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. DME and DR in Patients with DME: RISE—Phase III, multicenter, 3-year, sham injection–controlled study; primary end point at 2 years. RIDE—Phase III, long-term, 3-year, sham injection–controlled study; primary end point at 2 years.1-8

References: 1. LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2015. 2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related
macular degeneration. N Engl J Med. 2006;355:1419-1431. 3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy
for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65. 4. Regillo CD, Brown DM, Abraham P, et al; PIER Study Group. Randomized,
double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145:239-248. 5. Busbee BG, Ho AC, Brown DM,
et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology.
2013;120:1046-1056. 6. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results
of a phase III study. Ophthalmology. 2010;117:1102-1112. 7. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion:
six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-1133. 8. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic
macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.